Lupin is currently trading at Rs. 875.50, up by 3.05 points or 0.35% from its previous closing of Rs. 872.45 on the BSE.
The scrip opened at Rs. 876.00 and has touched a high and low of Rs. 882.90 and Rs. 873.00 respectively. So far 36,000 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 946.35 on 11-Oct-2013 and a 52 week low of Rs. 569.00 on 01-Mar-2013.
Last one week high and low of the scrip stood at Rs. 882.90 and Rs. 851.25 respectively. The current market cap of the company is Rs. 39,222 crore.
The promoters holding in the company stood at 46.78% while Institutions and Non-Institutions held 43.52% and 9.69% respectively.
Pharma Major Lupin (Lupin) has received final approval for its Abacavir Sulfate, Lamivudine, and Zidovudine Tablets, 300 mg (base) / 150 mg / 300 mg from the United States Food and Drugs Administration (FDA) to market a generic version of ViiV Healthcare's (ViiV)Trizivir Tablets, 300 mg (base) / 150 mg / 300mg.
Lupin's Abacavir Sulfate, Lamivudine, and Zidovudine Tablets, 300 mg (base) / 150 mg/ 300 mg is indicated in combination with other antiretrovirals or alone for the treatment of HIV-1 infection. Lupin was the first applicant to file an ANDA for Trizivir Tablets and as such will be entitled to 180 days of marketing exclusivity.
Trizivir Tablets, 300 mg (base) / 150 mg / 300mg had annual U.S sales of approximately $ 111.6 million (IMS MAT Sep, 2013).
The scrip opened at Rs. 876.00 and has touched a high and low of Rs. 882.90 and Rs. 873.00 respectively. So far 36,000 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 946.35 on 11-Oct-2013 and a 52 week low of Rs. 569.00 on 01-Mar-2013.
Last one week high and low of the scrip stood at Rs. 882.90 and Rs. 851.25 respectively. The current market cap of the company is Rs. 39,222 crore.
The promoters holding in the company stood at 46.78% while Institutions and Non-Institutions held 43.52% and 9.69% respectively.
Pharma Major Lupin (Lupin) has received final approval for its Abacavir Sulfate, Lamivudine, and Zidovudine Tablets, 300 mg (base) / 150 mg / 300 mg from the United States Food and Drugs Administration (FDA) to market a generic version of ViiV Healthcare's (ViiV)Trizivir Tablets, 300 mg (base) / 150 mg / 300mg.
Lupin's Abacavir Sulfate, Lamivudine, and Zidovudine Tablets, 300 mg (base) / 150 mg/ 300 mg is indicated in combination with other antiretrovirals or alone for the treatment of HIV-1 infection. Lupin was the first applicant to file an ANDA for Trizivir Tablets and as such will be entitled to 180 days of marketing exclusivity.
Trizivir Tablets, 300 mg (base) / 150 mg / 300mg had annual U.S sales of approximately $ 111.6 million (IMS MAT Sep, 2013).
No comments:
Post a Comment